With the FDA and EMA releasing their annual reports detailing novel drug approvals in 2024, a new pharmaphorum podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face in the year ahead.
Host Nicole Raleigh is joined by Cencora’s Sandra Anderson, SVP of International Commercialisation, and Chris Williams, SVP & International Managing Director at Alloga Europe and ICS, which are part of Cencora – and the conversation dives into takeaways such as the increase in smaller biotech companies taking their product to market on their own, what is needed to ensure a successful go-to-market strategy, the unique logistics and supply chain considerations specialty pharmaceutical products introduce, and also geographical considerations, with 34 of the 50 novel drugs approved in 2024 being in the US before any other country.
You can listen to episode 178a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!
--------
22:08
The ins and outs of HEOR – A lever for global health
ISPOR 2025, the leading global conference for Health Economics and Outcomes Research (HEOR), takes place 13th-16th May and marks the 30th anniversary of the organisation.
Ahead of the event, web editor Nicole Raleigh spoke with Rob Abbott, CEO and executive director of ISPOR – the leading professional society for HEOR globally – about the ins and outs and trends of HEOR.
ISPOR’s mission is to advance HEOR excellence to improve decision making for health globally, and Abbott explains its focus on the value of particular healthcare interventions, the impact on the quality of life of patients, and how his work is centred around positioning HEOR as a key lever for decision makers and shapers globally to create a world in which healthcare is accessible, effective, efficient, and affordable for everyone.
You can listen to episode 177a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!
--------
24:56
Unpacking Trumps executive order on drug pricing with Alice Valder Curran
President Donald Trump’s April 15th executive order, “Lowering Drug Prices by Once Again Putting Americans First”, contained a smorgasbord of policy proposals targeting a variety of industry stakeholders.
But how much legal force do these different elements have, and what are the concrete takeaways for pharma? To answer these questions and more, host Jonah Comstock once again welcomes Hogan Lovells attorney Alice Valder Curran to the podcast to pick apart the order piece by piece.
They discuss the headline – Trump’s intention to eliminate the Inflation Reduction Act’s “pill penalty”, and talk about why the language is more ambiguous than it appears and could be good or bad news for pharma.
They also talk about PBM reform, closing 340B loopholes, and how much the Federal government can really do to promote drug importation from Canada at the state level.
Check out the podcast to learn everything you wanted to know about Trump’s Executive Order.
--------
26:23
AI in drug development: The real hurdle is implementation
It can take up to 15 years for a new drug to reach the market, and with only 20% of pharmaceutical professionals adopting AI, one thing is clear: innovation in drug development is lagging behind.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrew Stelzer, head of business development at Unlearn.AI, about how the real hurdle in clinical research lies in effectively integrating AI.
Stelzer discusses the need for greater coordination within the pharmaceutical industry, particularly between life sciences and software engineering and explains how bridging the cultural divide can significantly enhance the adoption of emerging technologies like AI.
Of course, the conversation also touches upon the importance of collaboration, which can positively empower pharmaceutical companies to overcome existing challenges and drive significant advancements in drug development.
You can listen to episode 176a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!
--------
12:05
Patients as active consumers of care: AI-driven personalisation in pharma marketing
Therapy initiation, adherence, and health outcomes are being driven by artificial intelligence (AI)-powered personalisation. Today’s consumers are more active participants in their healthcare. Marketing in the era of consumer-driven healthcare requires new strategies to reach patients with the information they require, and how and when they need it.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Bill Grambley, CEO of AllazoHealth, for a conversation on leveraging AI for marketing, as well as medication initiation and adherence.
Grambley discusses how AI can be leveraged to create highly personalised patient engagement strategies, tailored to individual needs and preferences, as well as the technology can be used to identify patients at risk of medication non-adherence and intervene early to prevent negative outcomes.
The conversation touches upon the ethical implications of using AI to collect and analyse patient data, and how pharmaceutical companies are ensuring patient data privacy and security while leveraging AI to improve outcomes, in addition to the regulatory landscape and the future horizon.
You can listen to episode 175a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!
pharmaphorum is one of the leading global channels for insight into the pharma and healthcare industry – and is essentially a group of passionate people who like asking excellent questions. Our podcasts offer a chance to pose some of these questions to the keenest minds in our industry to look at the big issues and opportunities facing pharma, biotech and healthcare today. With interviews and contributions from a host of industry experts and insiders, the pharmaphorum podcast is a must-listen for those who want insight into the future of health and medicine.
Canada - english